Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular …
Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.
Drs. Eric Dein and Jonathan Kay discuss the state of biosimilars at the 2024 ACR Convergence meeting in Washington, DC.
Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.
Harrold et al. evaluate the fertility impact of checkpoint inhibitor blockade (ICB), demonstrating that unlike in utero exposure, post-exposure conception appears to result in uncomplicated pregnancies…
Did you know spending too much time sitting on the toilet could be bad for your health? I’m on @9news to explain why it could…
We reproduce the GPT-2 (124M) from scratch. This video covers the whole process: First we build the GPT-2 network, then we optimize its training to…
The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.
Join JACC editor-in-chief Harlan M. Krumholz, MD, SM, FACC, FAHA, and JACC Senior Advisor Milton Packer, MD, FACC, as they discuss the groundbreaking SUMMIT …
